Infinium Pharma

Why is Infinium Pharmachem Ltd falling/rising?

As of 19-Jun, Infinium Pharmachem Ltd's stock price is rising to 209.80, reflecting a 1.55% increase due to strong short-term performance and increased investor interest. The stock outperformed its sector and is above its short-term moving averages, indicating bullish momentum despite being below longer-term averages.

As of 19-Jun, Infinium Pharmachem Ltd's stock price is rising, currently at 209.80, reflecting a change of 3.2 or 1.55% increase. This upward movement can be attributed to several factors. Notably, the stock has outperformed its sector by 0.83% today, indicating positive market sentiment. Additionally, there has been a significant increase in investor participation, with delivery volume rising by 66.67% compared to the 5-day average, suggesting heightened interest from investors.<BR><BR>In terms of technical indicators, the stock is currently higher than its 5-day and 20-day moving averages, which typically signals bullish momentum. However, it is worth noting that it remains below its longer-term moving averages (50-day, 100-day, and 200-day), which could indicate some resistance at higher price levels.<BR><BR>Overall, the combination of strong short-term performance, increased trading volume, and positive sector comparison contributes to the current rise in Infinium Pharmachem Ltd's stock price.

Which are the latest news on Infinium Pharma?

What does Infinium Pharma do?

Infinium Pharmachem Ltd manufactures and sells Iodian-based pharmaceutical intermediates in the pharmaceuticals and biotechnology sector. It is a micro-cap company with a market cap of INR 328 Cr and a P/E ratio of 27.00.

Overview:<BR>Infinium Pharmachem Ltd is engaged in the manufacturing and selling of Iodian based Pharmaceutical Intermediates within the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History:<BR>Infinium Pharmachem Ltd was originally incorporated as "Infinium Pharmachem Private Limited" in 2003. The company later converted its status to a Public Company and changed its name to "Infinium Pharmachem Limited" in August 2022. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 328 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 27.00<BR>Industry P/E: 34<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -0.25<BR>Return on Equity: 10.04%<BR>Price-to-Book: 2.66<BR><BR>Contact Details:<BR>Registrar Address: Not available.

How big is Infinium Pharma?

As of 10th June, Infinium Pharmachem Ltd has a market capitalization of 328.00 Cr, classifying it as a Micro Cap company, with no valid financial data available for net sales or net profit for the latest four quarters. The balance sheet as of March 2025 shows Shareholder's Funds of 109.46 Cr and Total Assets of 198.24 Cr.

As of 10th June, <BR><BR>Market Cap: Infinium Pharmachem Ltd has a market capitalization of 328.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for net sales or net profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 109.46 Cr and Total Assets totaling 198.24 Cr.

Who are in the management team of Infinium Pharma?

The management team of Infinium Pharma includes Sanjaykumar Viththalbhai Patel (Chairman & Managing Director), Pravin Bhadabhai Madhani and Mitesh Lavjibhai Chikhaliya (Executive Directors), and independent directors Keyur Shah, Tarun Ratilal Dobariya, and Vaishakhi Ambrishbhai Shukla.

The management team of Infinium Pharma includes the following individuals:<BR><BR>1. **Sanjaykumar Viththalbhai Patel** - Chairman & Managing Director<BR>2. **Pravin Bhadabhai Madhani** - Executive Director<BR>3. **Mitesh Lavjibhai Chikhaliya** - Executive Director<BR>4. **Keyur Shah** - Independent Director<BR>5. **Tarun Ratilal Dobariya** - Independent Director<BR>6. **Vaishakhi Ambrishbhai Shukla** - Independent Director<BR><BR>If you need more information about their roles or the company's activities, feel free to ask!

Who are the peers of the Infinium Pharma?

Infinium Pharma's peers include Valiant Laborato, Medico Remedies, Medicamen Biotec, Ambalal Sarabhai, Trident Lifeline, Zenotech Lab., Transchem, Astonea Labs, and Gennex Lab. Infinium Pharma has below-average growth and management risk, with a 1-year return of -34.83%, better than Medicamen Biotec but worse than Trident Lifeline.

Peers: The peers of Infinium Pharma are Valiant Laborato, Medico Remedies, Medicamen Biotec, Ambalal Sarabhai, Trident Lifeline, Zenotech Lab., Transchem, Astonea Labs, and Gennex Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Medico Remedies and Gennex Lab., while Average management risk is found at Medicamen Biotec, Trident Lifeline, Zenotech Lab., Ambalal Sarabhai, and the rest. Below Average management risk is noted for Valiant Laborato, Infinium Pharma, and Transchem. In terms of Growth, Excellent growth is seen at Trident Lifeline, Good growth is observed at Valiant Laborato, Zenotech Lab., Astonea Labs, and Gennex Lab., while Average growth is found at Ambalal Sarabhai and Below Average growth is noted for Infinium Pharma, Medicamen Biotec, and Medico Remedies. For Capital Structure, Excellent capital structure is present at Medicamen Biotec and Infinium Pharma, Good capital structure is seen at Medico Remedies and Trident Lifeline, while Average capital structure is noted for Ambalal Sarabhai and Below Average capital structure is found at Valiant Laborato and Transchem.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Trident Lifeline at 0.00%, while the peer with the lowest 1-year return is Medicamen Biotec at -45.88%. Infinium Pharma's 1-year return of -34.83% is better than Medicamen Biotec's but worse than Trident Lifeline's. Additionally, the six-month return is negative for Medicamen Biotec, Infinium Pharma, and Ambalal Sarabhai.

Is Infinium Pharma overvalued or undervalued?

As of November 25, 2025, Infinium Pharma is fairly valued with a PE ratio of 43.23 and has underperformed the Sensex with a year-to-date return of -21.66%, indicating potential challenges in justifying its current price despite reasonable valuation compared to peers.

As of 25 November 2025, Infinium Pharma's valuation grade has moved from attractive to fair, indicating a shift in market perception. The company is currently fairly valued based on its financial metrics, with a PE ratio of 43.23, an EV to EBITDA of 23.31, and a ROE of 7.68%. Compared to its peers, Infinium Pharma's valuation appears reasonable; for instance, Sun Pharma is considered expensive with a PE of 36.81, while Cipla is attractive with a PE of 22.35.<BR><BR>Despite being fairly valued, Infinium Pharma has underperformed relative to the Sensex, with a year-to-date return of -21.66% compared to the Sensex's 9.47%. This underperformance, alongside its high valuation ratios, suggests that while the company is not overvalued, it may face challenges in justifying its current price in the near term.

How has been the historical performance of Infinium Pharma?

Infinium Pharma has demonstrated consistent growth in net sales, increasing from 99.12 Cr in March 2022 to 155.71 Cr in March 2025, but faced profitability challenges in the latest fiscal year, with profit after tax declining from 11.50 Cr in March 2024 to 7.84 Cr in March 2025. Total assets rose significantly, while cash flow from operating activities turned negative in March 2025.

Answer:<BR>The historical performance of Infinium Pharma shows a consistent growth trend in net sales and profits over the past four years.<BR><BR>Breakdown:<BR>Infinium Pharma's net sales have increased from 99.12 Cr in March 2022 to 155.71 Cr in March 2025, reflecting a steady upward trajectory. Total operating income followed a similar pattern, rising from 99.12 Cr to 155.71 Cr in the same period. However, total expenditure also grew, from 89.09 Cr in March 2022 to 139.29 Cr in March 2025, impacting operating profit which peaked at 20.07 Cr in March 2024 but fell to 18.54 Cr in March 2025. Profit before tax showed fluctuations, reaching 11.57 Cr in March 2025 after being 15.21 Cr in March 2024. The profit after tax decreased from 11.50 Cr in March 2024 to 7.84 Cr in March 2025. The company's total assets surged from 58.93 Cr in March 2022 to 198.24 Cr in March 2025, while total liabilities also increased significantly from 58.93 Cr to 198.24 Cr. Cash flow from operating activities turned negative in March 2025 at -29.00 Cr, contrasting with a positive cash flow in the previous years. Overall, while Infinium Pharma has shown growth in sales and assets, profitability has faced challenges in the latest fiscal year.

Who are the top shareholders of the Infinium Pharma?

The top shareholders of Infinium Pharma are Pravin Bhadabhai Madhani, the promoter with 12.2% ownership, and Ashish Kacholia, the highest public shareholder with 4.62%. Promoters hold the majority of shares, while individual investors own 32.0%, with no mutual funds or foreign institutional investors involved.

The top shareholders of Infinium Pharma include Pravin Bhadabhai Madhani, who is the promoter with the highest holding at 12.2%. Additionally, Ashish Kacholia is the highest public shareholder, holding 4.62%. The majority of the company's shares are held by promoters, and individual investors collectively own 32.0% of the shares. There are currently no mutual funds or foreign institutional investors holding shares in the company.

What is the technical trend for Infinium Pharma?

As of June 6, 2025, Infinium Pharma's technical trend is mildly bearish despite recent upward movement, with mixed signals from indicators like the bullish weekly MACD and bearish monthly RSI.

As of 6 June 2025, the technical trend for Infinium Pharma has changed from sideways to mildly bearish. The weekly MACD is bullish, but the monthly RSI indicates a bearish stance. Moving averages on the daily time frame are mildly bearish, while the weekly Dow Theory also supports a mildly bearish outlook. Bollinger Bands show a mildly bullish trend on both weekly and monthly time frames, which contrasts with the overall bearish sentiment. The stock is currently priced at 293.00, showing a recent upward movement from the previous close of 285.00, but the broader indicators suggest caution. Overall, the current technical stance is mildly bearish with mixed signals from various indicators.

When is the next results date for Infinium Pharma?

No Upcoming Board Meetings

What is the bonus history of the Infinium Pharma?

Infinium Pharma announced a 1:1 bonus issue, with an ex-date and record date of September 13, 2023, meaning shareholders will receive one additional share for each share they own. This is the latest update on their bonus history.

Infinium Pharma recently announced a bonus issue in a 1:1 ratio, with the ex-date being September 13, 2023. This means that shareholders will receive one additional share for every share they already own as of the record date, which is also September 13, 2023. This is the latest update regarding their bonus history. If you have any more questions about the company or its financial activities, feel free to ask!

Has Infinium Pharma declared dividend?

No Dividend History Available